To Study of Nephroprotective Activity of Zinnia Elegans Extract Against Gentamicin Induced Nephrotoxicity in Albino Rat

Gentamicin, which is one of the frequently prescribed aminoglycoside antibiotics, is very good at treating severe infections instigated by gram-negative pathogens. Nevertheless, its application is often constrained by the phenomenon of nephrotoxicity, which leads to the occurrence of acute kidney injury (AKI). It is normally characterized by both increased serum creatinine and blood urea nitrogen (BUN) and characteristic histopathological alterations of renal tissues e.g. in available serum, including tubular necrosis, glomerular moleculum damage, and interstitial inflammation. Subsequently there is a need to find remedy to safe and effective nephroprotective agents especially now that the clinical importance of gentamicin induced nephrotoxicity is known. An increased attention on natural products, especially the plant-based products, has been gained over the years owing to their ability to counter organ damage brought out by the drugs. Zinnia elegans is a flowering plant that belongs to Asteraceae family and it has extensive auspices of medicinal values such as antoxidants, anti-inflammatory, and antimicrobial. The plant also contains bioactive compounds, such as flavonoids, phenolic acids, and terpenoids, that have demonstrated a possible neutralization of oxidative stress, lowering inflammation, and maintenance of the kidney structure in many experimental models. The present review attempts to study the nephroprotective effect of Zinnia elegans extract on gentamicin-induced nephrotoxicity in terms of mechanisms of action and evidences based on preclinical investigations. Being the focus of this study, it examines how the plant is able to modulate oxidative stress, suppress pro-inflammatory cytokines and avert histopathological kidney damages. The paper also covers the molecular mechanisms behind these protective activities, and includes the importance of Zinnia elegans, which mediates these effects by reducing the apoptotic and inflammatory pathways, in the kidney. Further, the possible clinical use of the Zinnia elegans as a preventive drug against nephrotoxicity has been discussed which necessitates the necessity of clincal trials in future to confirm its efficacy and safety in humans. This review attempts to give an in-depth insight into the nephroprotective effects of Zinnia elegans in a bid to strengthen the already emerging evidence that dictate the use of natural products in the prevention and treatment of nephrotoxicity among patients on gentamicin therapy. The results outlined here might also encourage future researchers to investigate the clinical uses of Zinnia elegans in the renal process of nephroprotection with a possible complementary therapy in kidney complications.